[ad_1]
Elon Musk’s Neuralink, a brain-chip startup, announced that its experimental implant designed to restore vision has been granted the FDA’s “breakthrough device” designation. This designation is given to medical devices that address life-threatening conditions, aiming to expedite their development and review process.
The implant, named Blindsight, is said to enable individuals who have lost both eyes and their optic nerve to regain their vision, as stated by Musk. Neuralink, founded in 2016 by Musk and a team of engineers, is working on a brain chip interface that can be implanted in the skull to assist disabled patients in moving, communicating, and potentially restoring vision.
The device consists of a chip that processes and transmits neural signals, allowing communication with external devices such as computers or phones. Neuralink is also conducting trials on an implant that could help paralyzed patients operate digital devices solely through thought, offering hope to those with spinal cord injuries.
A clinical trial involving three patients is underway to evaluate the efficacy of the device, which is expected to span several years. Recently, the second patient successfully implanted with the device has been using it to play video games and learn 3D design.
Overall, Neuralink’s innovative technology holds promise for improving the quality of life for individuals with disabilities, offering new possibilities for communication and mobility.
[ad_2]
SOURCE
Emma Collins, graduated in Financial Economics from the University of Chicago in the USA in 2016. She has since worked at an asset management firm in New York, where she specializes in investment strategies and portfolio management. Emma has a keen interest in financial analysis and has published several articles in renowned financial journals. Her work focuses on providing actionable insights to investors, and she is known for her forward-thinking approach to managing financial portfolios.
